Publications by authors named "K K Rickard"
Article Synopsis
- Exacerbations in COPD are serious events that can worsen lung function and impair quality of life, highlighting the need for effective medication to manage them.
- Ensifentrine is a new drug that works as a dual inhibitor to reduce inflammation and open airways, and the study aimed to evaluate its effectiveness in reducing COPD exacerbation rates.
- The analysis from two phase 3 trials involving nearly 1,000 patients showed that ensifentrine significantly reduced both the frequency and risk of severe COPD exacerbations compared to a placebo across various patient subgroups.
Article Synopsis
- Dyspnea is a key concern in chronic obstructive pulmonary disease (COPD), and the study evaluated the effects of a drug called ensifentrine on this issue using data from Phase 3 trials.
- In the trials, ensifentrine was tested on 975 patients with COPD, showing significant improvements in dyspnea scores and reduced use of rescue medication after 24 weeks compared to 574 patients on a placebo.
- The study concluded that ensifentrine effectively alleviated dyspnea for moderate-to-severe COPD patients, although it did not include those already on certain combination therapies.
Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD.
Int J Chron Obstruct Pulmon Dis
August 2023
Article Synopsis
- Ensifentrine is a unique inhaled treatment that inhibits PDE3 and PDE4, helping with airway inflammation, bronchodilation, and ciliary function.
- In Phase 2 studies for COPD patients, it showed significant improvements in lung function, symptoms, and overall health quality, either alone or with other treatments.
- Currently, ensifentrine is in advanced clinical trials aimed at maintaining treatment for COPD patients, with this review focusing on its non-clinical and Phase 1 and 2 data on effectiveness and safety.
Article Synopsis
- Ensifentrine is a new medication that inhibits two enzymes linked to lung function, providing benefits such as bronchodilation and reduced inflammation for patients with chronic obstructive pulmonary disease (COPD).
- Two large trials (ENHANCE-1 and ENHANCE-2) showed that ensifentrine significantly improved lung function and reduced symptoms and exacerbation rates compared to a placebo, but results varied between the two trials.
- The studies involved nearly 1,600 patients with moderate to severe COPD, and ensifentrine was well-tolerated, with adverse events being similar to those experienced by patients on placebo.